| Identification | Back Directory | [Name]
1,6-Diazaspiro[3.4]octane-1-propanenitrile, 3-methyl-β-oxo-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, compd. with ethanol (1:1), (3S,4R)- | [CAS]
2064338-33-4 | [Synonyms]
1,6-Diazaspiro[3.4]octane-1-propanenitrile, 3-methyl-β-oxo-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-, compd. with ethanol (1:1), (3S,4R)- | [Molecular Formula]
C18H24N6O2 | [MOL File]
2064338-33-4.mol | [Molecular Weight]
356.43 |
| Hazard Information | Back Directory | [Description]
Delgocitinib, also known as LEO-124249 and JTE052, is a potent and selective JAK inhibitor. JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. JTE-052 regulates contact hypersensitivity by downmodulating T cell activation and differentiation. | [Uses]
Delgocitinib ethanolate is a specific JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively[1]. | [References]
[1] Tanimoto A, et al. Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2015 Jan;64(1):41-51. DOI:10.1007/s00011-014-0782-9 |
|
|